- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05608096
European Registry for Hemadsorption in Sepsis With the Seraph Filter
European Registry for Hemadsorption of Septic Patients With the Seraph 100 Microbind Affinity Blood Filter (ASTREA Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hemadsorption was introduced in everyday clinical practice before the COVID-19 pandemic. The efficacy of hemadsorption removal of endotoxins and cytokines is still, by some, controversial due to the fact that most of the studies were performed in a small number of patients with very different diagnoses, comorbidities and disease severity. Furthemore, some studies enrolled patients over a prolonged period of time with very high SOFA scores and multi-organ failure where it is difficult to expect any significant effect of any kind of organ support therapy. The COSA registry reported that the treatment of COVID-19 patients with Seraph 100 was well tolerated and observed lower mortality in the registry when compared to calculated mortality.
The primary aim of this observational prospective, multi-center, multistate web-based registry is to define the effectiveness and outcome of Seraph 100 treatment(s), investigate possible advantages of early targeted treatment and to set indications/inclusion criteria for the treatment of ICU septic patients with the method of hemoadsorption.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Grad Zagreb
-
Zagreb, Grad Zagreb, Croatia, 10000
- Recruiting
- University Hospital Center Zagreb
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Sepsis or septic shock: sepsis is defined as the presence of suspected or documented infections along with systemic inflammatory response syndrome; septic shock is defined as the presence of sepsis and acute circulatory failure according to European criteria Society for Intensive Care Medicine
- laboratory and clinical evidence of systemic inflammation: high levels of inflammatory cytokines such as IL-6 (>25 pg / ml); high values of inflammatory parameters from serum (leukocytes >15x10 9 / l, CRP >40 mg / l, procalcitonin >0.9 mg / l) and a high SOFA score (>2).
- clinical symptoms of hemodynamic instability requiring vasopressors
- diagnosis of ARDS
- deterioration of respiratory status with the onset of respiratory failure requiring mechanical ventilation (respiration rate >30 / min, or oxygen saturation <93%, or PaO2 / FiO2 ratio <300mmHg).
- Admission to ICU
Exclusion Criteria:
besides contraindications to the use of the hemoperfusion adopted (as from the manual of instructions), there are no exclusion criteria
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hemoperfusion
ICU septic patients treated with hemoperfusion
|
Commercial membrane for extracorporeal blood purification (hemoperfusion)
|
non-hemoperfusion
ICU septic patients non treated with hemoperfusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 28 days
|
Overall Survival after Seraph 100 therapy session
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Define the inclusion criteria for hemoperfusion with Seraph 100 in ICU septic patients
Time Frame: 28 days
|
Define the inclusion criteria for extracorporeal blood purification (hemoperfusion) with Seraph 100 in ICU septic patients
|
28 days
|
To assess the correlation between hemoperfusion and positive short-term outcome
Time Frame: Immediately after first hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability and respiratory status will be combined to report SOFA score)
|
Immediately after first hemoperfusion procedure
|
To assess the correlation between hemoperfusion and positive short-term outcome
Time Frame: Immediately after first hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in inflammatory status)
|
Immediately after first hemoperfusion procedure
|
To assess the correlation between hemoperfusion and positive short-term outcome
Time Frame: 72 hours after finishing the hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability and respiratory status will be combined to report SOFA score)
|
72 hours after finishing the hemoperfusion procedure
|
To assess the correlation between hemoperfusion and positive short-term outcome
Time Frame: 72 hours after finishing the hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in inflammatory status)
|
72 hours after finishing the hemoperfusion procedure
|
To assess the correlation between hemoperfusion and positive long-term outcome
Time Frame: 28 days
|
Define as to assess the correlation between hemoperfusion and positive long-term outcome, defined as patient survival at ICU discharge
|
28 days
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
Time Frame: Immediately after first hemoperfusion procedure in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
Define as to assess the effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e.
ECMO, CRRT) on positive short-term outcome (i.e.
improvement in hemodynamic stability and respiratory status will be combined to report SOFA score)
|
Immediately after first hemoperfusion procedure in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
Time Frame: Immediately after first hemoperfusion procedure in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
Define as to assess the effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e.
ECMO, CRRT) on positive short-term outcome (i.e.
improvement in inflammatory status)
|
Immediately after first hemoperfusion procedure in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
Time Frame: 72 hours after finishing the procedures with the combination of hemoperfusion and extracorporeal organ support therapy
|
Define as to assess the effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e.
ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability and respiratory status will be combined to report SOFA score)
|
72 hours after finishing the procedures with the combination of hemoperfusion and extracorporeal organ support therapy
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
Time Frame: 72 hours after finishing the procedures with the combination of hemoperfusion and extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
Define as to assess the effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e.
ECMO, CRRT) on positive short-term outcome (i.e.
improvement in inflammatory status)
|
72 hours after finishing the procedures with the combination of hemoperfusion and extracorporeal organ support therapies (i.e. ECMO, CRRT)
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome
Time Frame: 28 days
|
The effects of hemoperfusion in combination with other extracorporeal organ support therapies (i.e.
ECMO, CRRT) on positive long-term outcome, defined as patient survival at ICU discharge
|
28 days
|
To assess the correlation between hemoperfusion and negative short-term outcome
Time Frame: Immediately after first hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and negative short-term outcome (i.e. initial signs of humoral immune dysregulation (hypogammaglobulinemia defined as a gamma-globulin fraction below 10%) or cascade coagulation disorders (severe thrombocytopenia <15,000 cells/uL or severe bleeding)
|
Immediately after first hemoperfusion procedure
|
To assess the correlation between hemoperfusion and negative short-term outcome
Time Frame: 72 hours after finishing the hemoperfusion procedure
|
Define as to assess the correlation between hemoperfusion and negative short-term outcome (i.e. initial signs of humoral immune dysregulation (hypogammaglobulinemia defined as a gamma-globulin fraction below 10%) or cascade coagulation disorders (severe thrombocytopenia <15,000 cells/uL or severe bleeding)
|
72 hours after finishing the hemoperfusion procedure
|
Length of ICU stay
Time Frame: 28 days
|
Time spend in the ICU after Seraph 100 therapy session
|
28 days
|
Length of Hospital stay
Time Frame: 60 days
|
Time spend in the hospital after Seraph 100 therapy session
|
60 days
|
Adverse events
Time Frame: 28 days
|
Report of any Seraph 100 therapy related adverse events
|
28 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Inflammation
- Disease Attributes
- Disease
- Infant, Newborn, Diseases
- Shock
- Lung Injury
- Infant, Premature, Diseases
- Sepsis
- Syndrome
- Critical Illness
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Systemic Inflammatory Response Syndrome
- Multiple Organ Failure
Other Study ID Numbers
- ASTREA-1982
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityEnrolling by invitationSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on Hemoperfusion
-
Beijing Anzhen HospitalUnknown
-
Croatian Society for Organ SupportClinical Hospital Centre ZagrebEnrolling by invitationSystemic Inflammatory Response Syndrome | Critical Illness | Multi Organ Failure | COVID-19 Acute Respiratory Distress Syndrome | Viral Disease | AKI - Acute Kidney InjuryCroatia
-
Radboud University Medical CenterCytoSorbents Europe GmbHCompletedSepsis | Immune Deficiency | Hemoperfusion | Blood PurificationNetherlands
-
MedaSorb Technologies, IncCompletedSepsis | Acute Respiratory Distress Syndrome | Acute Lung InjuryGermany
-
Sun Yat-sen UniversityCompletedHyperparathyroidism | Insomnia | Refractory Pruritus | OstalgiaChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Shanghai Pudong HospitalCompleted
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruitingUremia | Dialysis Related Complication | Uremic OsteodystrophyChina
-
Chinese PLA General HospitalCompletedQuality of Life | Renal Dialysis | HemoperfusionChina
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted